Pharmaceutical exporter to Bangladesh

Yes. The Directorate General of Drug Administration accepts WHO-GMP certification from Indian manufacturing sites for dossier submissions, provided the certificate is current, issued by a recognised competent authority such as the Central Drugs Standard Control Organization or a state-level FDA, and accompanied by the manufacturing licence and recent inspection observations. DGDA's regulatory framework is structurally close to India's CDSCO model, which simplifies the documentation review for Indian-origin imports. Many of our source plants additionally hold EU-GMP certification, which carries weight on oncology and biologic submissions where DGDA reviewers value evidence of European-grade quality systems.

Because Bangladesh's domestic pharmaceutical industry is genuinely strong and meets roughly 97 per cent of domestic demand. Square Pharmaceuticals, Beximco Pharma, Incepta, and Renata operate well-equipped plants on commodity orals, basic injectables, and standard therapy categories, and they do so at price points that imported sea-freight product cannot reasonably match. Pretending otherwise would waste the buyer's time and ours. Our genuine value lies in oncology injectables, monoclonal antibodies, biologics, second-line anti-infectives, and complex specialised injectables where Bangladeshi domestic capacity has not yet developed. The regulatory rationale for import is clearer in those categories, the price math works, and the procurement preference does not collide with industrial-policy framing.

From Mumbai Nhava Sheva to Chittagong port we plan for nine to fourteen days of port-to-port transit on direct or single-transhipment services. Colombo and Singapore are the common transhipment hubs. This is among the shortest sea legs we operate internationally because Bangladesh sits geographically close to the Indian western coast. We add three to five working days for Bangladeshi customs clearance buffer at Chittagong, with our broker pre-filing import documentation while the vessel is still at sea so the customs clock starts before the container lands. Cold-chain biologics ship by air rather than sea, with 24 to 36 hour transit on Biman Bangladesh or Indian carriers into Dhaka.

Yes, in many cases. Following the Reserve Bank of India's 2023 international trade settlement framework that permits invoicing in Indian rupees with overseas correspondents, several Bangladeshi banks now offer INR-denominated trade settlement under the South Asian Association for Regional Cooperation framework. We invoice in either USD or INR according to the importer's preference and banking arrangement, and we provide all documentation in the form the Bangladeshi authorised dealer bank requires for the chosen settlement currency. INR settlement can reduce currency-conversion friction for importers managing taka-rupee exposure rather than taka-dollar.

DGDA timelines for a complete CTD dossier are typically eight to fourteen months for new generic registrations and twelve to eighteen months for biologics and complex injectables, with real-world variation depending on dossier completeness, queries during review, and the therapy category. Our experience is that registrations in our focus categories of oncology, biologics, and specialised injectables clear toward the lower half of that range because the regulatory rationale for import is clear. Where we have already filed the same molecule in Sri Lanka, the Philippines, or another South Asian or Asian market, we adapt those dossiers for DGDA rather than rewriting from scratch, which compresses the authoring phase considerably.

For certain cargo categories yes. The Petrapole, India and Benapole, Bangladesh land border crossing handles a meaningful share of India-Bangladesh pharmaceutical road freight, particularly for non-cold-chain SKUs originating in eastern Indian manufacturing belts and destined for Dhaka or northern Bangladesh. Transit can be quicker than sea freight for those origin-destination pairs, but customs procedures, transhipment requirements between Indian and Bangladeshi trucks, and documentation handling are different from sea freight. We assess the road option on a case-by-case basis where the source plant location and the cargo profile make it sensible. Most of our Mumbai-origin shipments default to Mumbai-Chittagong sea routing.

Bangladesh has experienced periods of political disruption that have affected logistics in past years, and we plan supply continuity accordingly. Our standard practice for time-sensitive shipments includes maintaining buffer stock at the importer's licensed warehouse, splitting consignment volumes across multiple shipments rather than concentrating risk, and using air freight as fallback routing when sea-freight or border conditions are uncertain. We monitor port operations at Chittagong and Mongla, customs processing at Hazrat Shahjalal, and broader transport conditions through our Dhaka logistics partners, and we communicate proactively with importers when conditions warrant rerouting or rescheduling. Cold-chain biologic shipments are scheduled with extra contingency given the consequences of temperature excursion.